At this point, her oncologist informed her of a recent study showing an 87% complete response rate at three years for relapsed refractory HCL patients with a drug combination of BRAF inhibitor with rituximab; however, due to her previous life-threatening allergic reaction to rituximab, she was not eligible for this medication combination. The gene discussed is BRAF; the disease is hairy cell leukemia.